Targets › RNAP
4 programs from 3 companies in 7 trials: 5 Phase 2, 1 Phase 4, 1 Phase 3; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on RNAP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Huashan Hospital | Rifapentine Bacterial DNA-directed RNA polymerase inhibitor | RNAP | Phase 4 | Tuberculosis; Tuberculosis, Pulmonary | Nov 2027 |
| Institute of Tropical Medicine, Belgium | rifampicin (BE-PEP) RNA polymerase inhibitor | RNAP | Phase 3 | Leprosy | Mar 2027 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRB, RNAP | Phase 2 | Tuberculosis Infection, Latent | Apr 2027 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Rifampin Bacterial DNA-directed RNA polymerase inhibitor | RNAP | Phase 2 | Tuberculosis Infection, Latent | Apr 2027 |
Tuberculosis, Pulmonary (3) Tuberculosis Infection, Latent (2) Tuberculosis (1) Leprosy (1)
small molecule (3)
McGill University Health Centre/Research Institute of the McGill University Health Centre (2) Huashan Hospital (1) Institute of Tropical Medicine, Belgium (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.